These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 21195884)

  • 41. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence.
    Campbell JD; Gries KS; Watanabe JH; Ravelo A; Dmochowski RR; Sullivan SD
    BMC Urol; 2009 Nov; 9():18. PubMed ID: 19930578
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overactive bladder (OAB): A symptom in search of a disease - Its relationship to specific lower urinary tract symptoms and conditions.
    Van Batavia JP; Combs AJ; Fast AM; Glassberg KI
    J Pediatr Urol; 2017 Jun; 13(3):277.e1-277.e4. PubMed ID: 28527720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyaluronic acid-chondroitin sulfate: a potential factor to select pure stress urinary incontinence in patients with interstitial cystitis⁄painful bladder syndrome and mixed incontinence symptoms.
    Morelli M; Mocciaro R; Venturella R; Albano A; Sacchinelli A; Zullo F
    Minerva Ginecol; 2015 Apr; 67(2):121-5. PubMed ID: 25763801
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder.
    Haab F; Braticevici B; Krivoborodov G; Palmas M; Zufferli Russo M; Pietra C
    Neurourol Urodyn; 2014 Mar; 33(3):335-40. PubMed ID: 23765630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ultrasound assessment of bladder wall thickness as a screening test for detrusor instability.
    Abou-Gamrah A; Fawzy M; Sammour H; Tadros S
    Arch Gynecol Obstet; 2014 May; 289(5):1023-8. PubMed ID: 24276424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence.
    van Gool JD; de Jong TP; Winkler-Seinstra P; Tamminen-Möbius T; Lax H; Hirche H; Nijman RJ; Hjälmås K; Jodal U; Bachmann H; Hoebeke P; Walle JV; Misselwitz J; John U; Bael A;
    Neurourol Urodyn; 2014 Jun; 33(5):482-7. PubMed ID: 23775924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urgency assessment in the evaluation of overactive bladder (OAB).
    Starkman JS; Dmochowski RR
    Neurourol Urodyn; 2008; 27(1):13-21. PubMed ID: 17671973
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimuscarinics and bladder outlet obstruction: From a contraindication to an indication?
    Athanasopoulos A
    Neurourol Urodyn; 2010; 29 Suppl 1():S46-50. PubMed ID: 20127792
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
    Haab F
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S2-5. PubMed ID: 25042138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics.
    Cho KJ; Kim HS; Koh JS; Kim JC
    Int Urogynecol J; 2013 Feb; 24(2):325-30. PubMed ID: 22717785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S; Oo N
    J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.
    Hsiao SM; Lin HH; Kuo HC
    Neurourol Urodyn; 2014 Mar; 33(3):331-4. PubMed ID: 23494586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Modern approaches to the treatment of patients with overactive bladder and urge urinary incontinence].
    Razdorskaia MV; Neĭmark AI; Aliev RT
    Urologiia; 2013; (1):44-6, 48-9. PubMed ID: 23662495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 May; 107(10):1612-7. PubMed ID: 21070569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary nerve growth factor correlates with the severity of urgency and pain.
    Kim SW; Im YJ; Choi HC; Kang HJ; Kim JY; Kim JH
    Int Urogynecol J; 2014 Nov; 25(11):1561-7. PubMed ID: 24866276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.